P
Parenteral Drugs
PDPL NSE
Parenteral Drugs
HealthcareNSE: PDPL BSE: 524689 Pharmaceuticals & Biotechnology
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
1- Company has reduced debt.
Weaknesses
4- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -48.3% over past five years.
- Contingent liabilities of Rs.135 Cr.
- Company's cost of borrowing seems high
Growth Rate
Revenue Growth
-30% higher than
3Y
Net Income Growth
-6% lower than
3Y
Quarterly Results
| Particulars | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2 | 9 | 7 | 7 | 9 | 3 | 5 | 2 | 3 | 3 | 2 | 1 | 2 |
| Expenses | 12 | 13 | 11 | 10 | 13 | 9 | 11 | 5 | -1 | 6 | 6 | 5 | 8 |
| Operating Profit | -9 | -4 | -4 | -3 | -4 | -6 | -6 | -3 | 3 | -3 | -3 | -3 | -6 |
| OPM % | -387% | -46% | -50% | -41% | -48% | -200% | -139% | -141% | 132% | -90% | -139% | -224% | -333% |
| Other Income | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 52 |
| Interest | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 32 | 34 | 35 | 37 | 0 |
| Depreciation | 55 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 27 |
| PBT | -88 | -34 | -35 | -35 | -37 | -40 | -42 | -39 | -33 | -41 | -43 | -44 | 19 |
| Tax % | -18% | -19% | -19% | -26% | -13% | -19% | -19% | -21% | -26% | -22% | -22% | -22% | -24% |
| Net Profit | -72 | -28 | -28 | -26 | -32 | -32 | -34 | -31 | -25 | -32 | -34 | -35 | 24 |
| EPS in Rs | -24.13 | -9.29 | -9.49 | -8.77 | -10.71 | -10.81 | -11.29 | -10.39 | -8.33 | -10.75 | -11.27 | -11.58 | 7.99 |
Profit & Loss
| Particulars | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 482 | 333 | 327 | 274 | 263 | 260 | 230 | 224 | 32 | 32 | 12 | 8 |
| Expenses | 433 | 319 | 341 | 349 | 248 | 296 | 249 | 225 | 50 | 47 | 24 | 24 |
| Operating Profit | 50 | 14 | -14 | -75 | 14 | -36 | -19 | -1 | -18 | -15 | -12 | -15 |
| OPM % | 10% | 4.2% | -4.3% | -27% | 5% | -14% | -8% | -0.5% | -55% | -46% | -97% | -177% |
| Other Income | 1 | 0 | 0 | 107 | 1 | 2 | 3 | 2 | 1 | 0 | 0 | 52 |
| Interest | 29 | 48 | 56 | 60 | 70 | 70 | 86 | 98 | 96 | 110 | 125 | 106 |
| Depreciation | 13 | 14 | 23 | 19 | 31 | 23 | 25 | 24 | 69 | 17 | 17 | 40 |
| PBT | 9 | -49 | -93 | -47 | -86 | -127 | -127 | -121 | -181 | -142 | -154 | -109 |
| Tax % | 46% | 10% | 16% | -3% | -22% | -8% | -8% | -8% | -18% | -20% | -21% | -30% |
| Net Profit | 5 | -53 | -108 | -45 | -68 | -117 | -118 | -112 | -148 | -114 | -122 | -76 |
| EPS in Rs | 1.71 | -20.64 | -41.69 | -15.15 | -22.69 | -39.09 | -39.52 | -37.5 | -49.61 | -38.26 | -40.82 | -25.61 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Balance Sheet
| Particulars | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 26 | 26 | 26 | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 30 |
| Reserves | 300 | 311 | 203 | 157 | 82 | 278 | -47 | -166 | -477 | -591 | -713 | -854 |
| Borrowings | 332 | 395 | 501 | 539 | 581 | 670 | 772 | 767 | 638 | 636 | 636 | 107 |
| Other Liabilities | 97 | 118 | 105 | 98 | 92 | 88 | 159 | 260 | 349 | 478 | 615 | 1,201 |
| Total Liabilities | 755 | 850 | 835 | 825 | 785 | 1,066 | 914 | 890 | 541 | 552 | 568 | 484 |
| Fixed Assets | 406 | 500 | 610 | 571 | 542 | 892 | 739 | 716 | 356 | 339 | 322 | 205 |
| CWIP | 79 | 116 | 4 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 4 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 2 | 2 | 2 |
| Other Assets | 267 | 233 | 221 | 253 | 242 | 174 | 175 | 175 | 182 | 210 | 244 | 276 |
| Total Assets | 755 | 850 | 835 | 825 | 785 | 1,066 | 914 | 890 | 541 | 552 | 568 | 484 |
Cash Flow
| Particulars | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 78 | 20 | -168 | -60 | 2 | 58 | 134 | 167 | 477 | 112 | 125 | 0 |
| Investing | -113 | -147 | -18 | 33 | 3 | -110 | -1 | -1 | 97 | 0 | 0 | 65 |
| Financing | 31 | 133 | 182 | 25 | -10 | 54 | -134 | -167 | -574 | -112 | -125 | -64 |
| Net Cash Flow | -5 | 5 | -3 | -2 | -5 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free Cash Flow | -31 | -127 | -188 | -38 | -3 | -52 | 134 | 166 | 576 | 112 | 125 | 64 |
| CFO/OP | 164 | 143 | 1,193 | 77 | 12 | -162 | -692 | -14,269 | -2,700 | -765 | -1,065 | 3 |
Ratios
| Particulars | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 81 | 101 | 88 | 161 | 194 | 130 | 99 | 6 | 0 | 0 | 0 | 0 |
| Inventory Days | 118 | 149 | 121 | 128 | 232 | 112 | 107 | 68 | 224 | 73 | 103 | 69 |
| Days Payable | 79 | 157 | 112 | 99 | 177 | 77 | 101 | 130 | 671 | 458 | 504 | 654 |
| Cash Conversion Cycle | 120 | 93 | 97 | 189 | 249 | 164 | 105 | -55 | -446 | -385 | -401 | -585 |
| Working Capital Days | -19 | -73 | 22 | 34 | 3 | -198 | -491 | -810 | -9,244 | -10,747 | -32,260 | -48,682 |
| ROCE % | 6% | 0% | -5% | -4% | -2% | -7% | -5% | -3% | -21% | -24% | -213% | — |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Parenteral Drugs insights
64 extracted metrics + investor summaries across FY08–FY22.
Documents
1
Corporate Insolvency Resolution Process (CIRP)-Approval of Resolution plan by Tribunal
23 Jan 2025 - NCLT approved resolution plan for Parenteral Drugs (India) Ltd. 23 Jan 2025 - NCLT approved resolution plan for Parenteral Drugs (India) Ltd.
2
Corporate Insolvency Resolution Process (CIRP)-Approval of Resolution plan by Tribunal
22 Jan 2025 - NCLT approves resolution plan for Parenteral Drugs. 22 Jan 2025 - NCLT approves resolution plan for Parenteral Drugs.
3
Corporate Insolvency Resolution Process (CIRP)-Outcome of meeting of Committee of Creditors
7 Dec 2024 - Post-facto intimation of CoC meeting held. 7 Dec 2024 - Post-facto intimation of CoC meeting held.
4
Corporate Insolvency Resolution Process (CIRP)-Intimation of meeting of Committee of Creditors
5 Dec 2024 - Meeting of Committee of Creditors scheduled for December 5, 2024. 5 Dec 2024 - Meeting of Committee of Creditors scheduled for December 5, 2024.
5
Corporate Insolvency Resolution Process (CIRP)-Outcome of meeting of Committee of Creditors
10 Sep 2024 - Post-facto intimation of CoC meeting held. 10 Sep 2024 - Post-facto intimation of CoC meeting held.
3
Corporate Insolvency Resolution Process (CIRP)-Outcome of meeting of Committee of Creditors 7 Dec 2024
Company Update
4
Corporate Insolvency Resolution Process (CIRP)-Intimation of meeting of Committee of Creditors 5 Dec 2024
Company Update
5
Corporate Insolvency Resolution Process (CIRP)-Outcome of meeting of Committee of Creditors 10 Sept 2024
Company Update
Frequently Asked Questions about Parenteral Drugs
What does Parenteral Drugs (India) Ltd do?
Incorporated in 1983, Parenteral Drugs Ltd
is engaged in Manufacturing and Trading of Pharmaceutical Products
Where is Parenteral Drugs (India) Ltd (PDPL) listed?
Parenteral Drugs (India) Ltd trades as PDPL on the NSE and under code 524689 on the BSE.
Which sector does Parenteral Drugs (India) Ltd belong to?
Parenteral Drugs (India) Ltd is classified under the Healthcare sector, in the Pharmaceuticals & Biotechnology industry.
Company Information
Incorporated in 1983, Parenteral Drugs Ltd is engaged in Manufacturing and Trading of Pharmaceutical Products
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/PDPL.md for Parenteral Drugs (India) Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.